This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
PE-Labeled Human LAG-3 / CD223 Protein, His Tag (recommended for neutralizing assay)
catalog :
LA3-HP2H3
quantity :
250 tests, 50 tests
price :
1050 USD, 300 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
LA3-HP2H3
product name :
PE-Labeled Human LAG-3 / CD223 Protein, His Tag (recommended for neutralizing assay)
quantity :
250 tests, 50 tests
price :
1050 USD, 300 USD
quantity & price :
$300/50tests,$1050/250tests
target :
LAG-3
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
PE-Labeled Human LAG-3, His Tag (Cat. No. LA3-HP2H3) is produced via site-specific conjugation of PE to Human LAG-3, His Tag under optimal conditions with a proprietary technology. Human LAG-3, His Tag is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Leu 450 (Accession # P18627-1).
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS with Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please protect from light and avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.
References :
(1) Triebel F., et al., 1990, J. Exp. Med. 171:1393-1405.
(2) Baixeras E., et al., 1992, J. Exp. Med. 176:327-337.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments